Preclinical models
In vivo Distribution of Inorganic Nanoparticles in Preclinical Models
... in preclinical models is required before any application in ...different preclinical models, particularly mouse, rat and ...in preclinical models: gold nanoparticles, silica ...
11
Developing preclinical models of neuroblastoma: driving therapeutic testing
... Many preclinical models attempt to mimic the tumor phenotype and tumor ...mouse models, in the form of genetic, syngeneic, and xenograft mice, are advantageous as they replicated the complex ...
18
Imaging technologies for preclinical models of bone and joint disorders
... the preclinical SPECT scanners are equipped with multipinhole colli- mators to acquire high spatial resolution of foci of gamma-emitting tracers within the subject ...of preclinical PET scanner lies in the ...
14
Original Article Stability of preclinical models of aggressive renal cell carcinomas
... [11] Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Con- treras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon ...
13
Anti tumour activity of bisphosphonates in preclinical models of breast cancer
... cancer models, BPs aff ect a range of cell types contributing to tumour development, including those of the local and distal tumour microenvironment (Figures 2 and ...
13
V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
... Fig. 2 Bronchoprotection and anti-inflammatory effects of intratracheal V0162 single-dose in preclinical models. a Effect over time of V0162 and tiotropium on bronchoconstriction induced by acetylcholine in ...
12
Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
... ES is characterized by extensive bone destruction due to osteolysis. Ewing ' s sarcoma cells are unable to directly degrade the bone matrix and accordingly, osteoclast activation and sub- sequent bone resorption might be ...
10
2017_Moody.pdf
... approximate drug concentrations within brain tissue; however, for reasons previously listed, drug concentrations in these compartments do not necessarily reflect those in the brain. The objective of this study was to ...
11
A signaling pathway AKTing up in schizophrenia
... in preclinical models have demonstrated that impaired AKT signaling affects neuronal connectivity and neuromodulation and have identified AKT as a key signaling intermediary downstream of dopamine (DA) ...
5
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
... several preclinical models of lung metastasis. In all models examined, the lung metastases co-opted alveolar capillaries by occupying the alveolar air spaces ...
58
The potential benefit of stem cell therapy after stroke: an update
... A number of different types of stem cells, obtained from different sources, have been shown to improve clinical and radiological outcomes in preclinical models of stroke. The choice of cell type for ...
12
Epilepsy: the next generation drugs (a review)
... in preclinical models of epilepsy and has demonstrated a favorable efficacy and tolerability profile in a Phase II clinical ...seizure models 21 ...
7
Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review
... of preclinical models report the use of two main cell types: early-outgrowth endothelial pro- genitor cells (EPCs, also known as circulating angiogenic cells, myeloid angiogenic cells) and mesenchymal stro- ...
14
Sodium channel-inhibiting drugs and cancer survival : protocol for a cohort study using the CPRD primary care database
... Introduction: Voltage-gated sodium channel (VGSC)- inhibiting drugs are commonly used to treat epilepsy and cardiac arrhythmia. VGSCs are also widely expressed in various cancers, including those of the breast, bowel and ...
10
Schuck_unc_0153D_13906.pdf
... Moreover, the impact of these medications (most notably aspirin which modifies prostanoid levels) on CYP-mediated eicosanoid metabolism has not been rigorously evaluated in preclinical models or humans, and ...
219
The role of bisphosphonates in breast cancer: Actions of bisphosphonates in animal models of breast cancer
... in preclinical models of breast cancer metastases to bone illustrate the impor- tance of the bone microenvironment and osteoclastic bone resorption in the development of skeletal metastases of both ...
7
Caron_unc_0153D_14054.pdf
... Next, in Aim 2, we evaluated the function of MO/DC in blood and compared this to the function seen in tissue macrophages, such as Kupffer cells and splenic macrophages. We studied a variety of species, including mice, ...
176
Prinz, Christoph (2018): Biopharmaceutical characterization of porcine mesenchymal stromal cells as a model system for a human cell therapy product. Dissertation, LMU München: Medizinische Fakultät
... The efficiency of homing (and the efficacy of the therapeutic suicide gene) is still challenging this therapeutic approach. Preclinical models with myocardial infarction all[r] ...
161
New cast for a new era: preclinical cancer drug development revisited
... Another obstacle is failed engraftment of transplanted material, which can be greater than 90%, depending on the type of cancer (30). These engraftment failures may be due to the absence of a tumor-supporting niche ...
8
Neurostimulation of the Cholinergic Antiinflammatory Pathway in Rheumatoid Arthritis and Inflammatory Bowel Disease
... Pharmacologic activation using α7nAChR-selective and nonselective CAP activators, and CAP inhibition by vago- tomy have been studied extensively in the mucosal irritant, hapten-mediated, and IL- 10 knockout models ...
10